Official title and information are available only for Plus and Premium subscribers.
Patent Pending Erythropoietins available for use as therapeutic agents are produced by recombinant DNA technology in cell culture, and include Epogen/Procrit (epoetin alfa) and Aranesp (darbepoetin alfa); they are used in treating anemia resulting from chronic kidney disease, inflammatory bowel disease (Crohn's disease and ulcer colitis) [18] and myelodysplasia from the treatment of cancer (chemotherapy and radiation).
To see the additional information details please login and subscribe to a Plus or Premium account.
